在接受来那度胺、硼替佐米、地塞米松和移植治疗的多发性骨髓瘤患者中预测静脉血栓栓塞:IFM/DFCI 2009队列子研究的启示
该研究为IFM 2009随机对照试验的子研究,评估700例接受来那度胺/硼替佐米/地塞米松(联合或不联合自体造血干细胞移植)的新诊断多发性骨髓瘤患者的静脉血栓栓塞(VTE)发生率、危险因素和风险评分。6个月VTE发生率为4.8%(95%CI 3.3-6.9%),6至12个月为1.5%(95%CI 0.8-2.9%)。多因素分析证实VTE病史为强危险因素(OR 5.1,95%CI 1.6-16.7,P=.007),排除促红细胞生成素暴露(OR 0.6,95%CI 0.2-1.7,P=.3),新增诊断时骨折(OR 2.6,95%CI 1.3-5.5,P=.01)和血清丙种球蛋白>27 g/L(OR 2.8,95%CI 1.2-6.8,P=.02)两个危险因素。
要点
- 6个月VTE发生率为4.8%,6至12个月为1.5%。
- VTE病史(OR 5.1)、诊断时骨折(OR 2.6)、丙种球蛋白>27 g/L(OR 2.8)与VTE风险相关。
- 肝素使用与VTE风险降低相关(OR 0.3),但无论剂量如何均未能消除风险。
核心结论
- 基于上述结果,需要开展前瞻性研究以改善VTE风险分层,并在时机和剂量方面设计合适的血栓预防方案。
研究设计与样本
- 该研究为IFM 2009随机对照试验的子研究,评估700例接受来那度胺/硼替佐米/地塞米松治疗(联合或不联合自体造血干细胞移植)的新诊断多发性骨髓瘤患者。
主要发现
- 6个月VTE发生率为4.8%(95%CI 3.3-6.9%),6至12个月为1.5%(95%CI 0.8-2.9%)。
- 多因素分析证实VTE病史为强VTE相关危险因素(OR 5.1,95%CI 1.6-16.7,P=.007),排除促红细胞生成素暴露作为危险因素(OR 0.6,95%CI 0.2-1.7,P=.3)。
- 新增两个危险因素:诊断时骨折(OR 2.6,95%CI 1.3-5.5,P=.01)和血清丙种球蛋白水平>27 g/L(OR 2.8,95%CI 1.2-6.8,P=.02)。
- 丙种球蛋白水平>27 g/L的患者VTE发生更早,提示需要重新审视血栓预防的时间框架。
- 肝素使用与风险降低相关(OR 0.3,95%CI 0.1-0.7,P=.005),但无论剂量如何均未能消除风险;IMPEDE VTE评分的受试者工作特征曲线下面积为0.67,与既往报道一致,证实该队列具有良好代表性。
关键数值与推荐
- VTE病史:OR 5.1(95%CI 1.6-16.7),P=.007。
- 诊断时骨折:OR 2.6(95%CI 1.3-5.5),P=.01。
- 血清丙种球蛋白>27 g/L:OR 2.8(95%CI 1.2-6.8),P=.02。
- 肝素使用:OR 0.3(95%CI 0.1-0.7),P=.005。
- 促红细胞生成素暴露:OR 0.6(95%CI 0.2-1.7),P=.3。
临床怎么用
- 作者认为需要前瞻性研究来改善VTE风险分层,并在时机和剂量方面设计合适的血栓预防方案。
局限性
- 需要开展前瞻性研究以改善VTE风险分层并设计合适的血栓预防方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Venous thromboembolism (VTE) is a concern for patients with newly diagnosed multiple myeloma. OBJECTIVES: We aimed to evaluate VTE incidence, risk factors, and risk score. PATIENTS/METHODS: We performed a substudy of the "Intergroupe Francophone du Myelome 2009" randomized controlled trial. RESULTS: We assessed 700 patients receiving lenalidomide/bortezomib/dexamethasone, followed or not by autologous hematopoietic stem cell transplantation. VTE incidence at 6 months was 4.8% (95% confidence interval [CI]: 3.3-6.9%) and 1.5% (95% CI: 0.8-2.9%) from 6 to 12 months. Using multivariate analysis we confirmed history of VTE (odds ratio 5.1 [1.6-16.7], P = .007) as a strong VTE-related risk factor, invalidated erythropoietin exposure (0.6 [0.2-1.7], P = .3) as risk factor, and added two new risk factors: fracture at diagnosis (2.6 [1.3-5.5], P = .01), and serum gamma globulin level > 27 g/L (2.8 [1.2-6.8,] P = .02). Moreover, we noticed that VTE occurred earlier in patients with gamma globulin levels >27 g/L, suggesting a need to revisit the thromboprophylaxis timeframe. Heparin administration was associated with a decreased risk (0.3 [0.1-0.7], P = .005) but failed to erase the risk regardless of dose. The area under the receiver operating characteristic curve of the IMPEDE VTE score was 0.67, as previously reported, confirming our cohort was well representative. CONCLUSIONS: Prospective studies are warranted in light of these results to improve VTE risk stratification and to design adapted thromboprophylaxis in terms of timing and dose.
引用
- Chalayer E, Talbot A, Frenzel L, et al. Prediction of venous thromboembolism in patients with multiple myeloma treated with lenalidomide, bortezomib, dexamethasone, and transplantation: Lessons from the substudy of IFM/DFCI 2009 cohort. J Thromb Haemost. 2022. PMID: 35557490. doi:10.1111/jth.15758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。